Form 4: Sutro Biopharma CFO Granted 8,200 Stock Options
Insider Transaction Report
Sutro Biopharma's CFO, Gregory K. Chow, was granted 8,200 stock options with a vesting schedule over 48 months.
Summary
- Gregory K. Chow, Chief Financial Officer of Sutro Biopharma, Inc. (STRO), was granted 8,200 stock options.
- The stock options have an exercise price of $10.38 per share.
- The transaction date for this grant was December 23, 2025.
- The options will vest monthly over a 48-month period, with the first tranche vesting on January 23, 2026.
- The options are set to expire on December 23, 2035.
Sentiment
Score: 7
Explanation: The grant of stock options to a key executive is a positive signal for management retention and alignment with shareholder interests, reflecting standard compensation practices.
Positives
- The grant of stock options aligns the CFO's financial interests with those of shareholders, incentivizing long-term company performance.
- The four-year vesting schedule encourages the retention of a key management executive, providing stability in leadership.
Future Outlook
The vesting schedule for the stock options indicates an expectation of continued service from the CFO for at least the next four years, suggesting stability in key management.
Industry Context
The grant of stock options to a key executive like the CFO is a standard practice in the biotechnology industry to attract, retain, and incentivize talent, aligning their performance with company growth and shareholder value creation.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Grant | Gregory K. Chow granted a Limited Power of Attorney to Regina Cheng and David Pauling to execute and file Forms 3, 4, and 5 on his behalf. | 2025-10-07 | Streamlines the SEC filing process for insider transactions by the CFO, ensuring timely compliance. |
Stakeholder Impact
- Shareholders: Potential for increased alignment of the CFO's interests with shareholder value creation; potential for minor future dilution upon exercise of options.
- Employees: Signals stability in executive leadership.
Next Steps
- Continued monthly vesting of the stock options over the next 48 months, subject to Gregory K. Chow's continued service to the issuer.
Key Dates
| Date | Description |
|---|---|
| 2025-10-07 | Date Gregory Chow executed the Limited Power of Attorney for SEC filings. |
| 2025-12-23 | Date of stock option grant to Gregory K. Chow. |
| 2025-12-29 | Date the Form 4 was signed by attorney-in-fact. |
| 2026-01-23 | First vesting date for the stock options. |
| 2035-12-23 | Expiration date of the stock options. |
Recommendation
holdThis Form 4 reports a routine stock option grant to a key executive, which is a standard compensation practice. It does not contain information that would fundamentally alter the investment thesis for Sutro Biopharma, hence a 'hold' recommendation is appropriate, maintaining existing positions based on broader company fundamentals rather than this specific filing.
Keywords
Sutro Biopharma, STRO, Stock Options, CFO, Executive Compensation, Insider Transaction, Form 4, Equity Grant, Vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.